Comprising 53% of the entire tumor, cluster 3 demonstrated low HER2 uptake and increased cellular density (decreased ADC), suggesting a large subtumoral population of low HER2-expressing regions that are actively proliferating and less likely to respond to HER2-targeted treatment. Here, ERBB2 is linked to neoplasm.